The injectable drug delivery devices market size has grown strongly in recent years. It will grow from $54.3 billion in 2025 to $58.69 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, expansion of biologics and biosimilars, increasing hospital-based injectable treatments, improvements in sterile manufacturing practices, wider availability of injection devices.
The injectable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $79.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing shift toward self-administration devices, rising demand for personalized drug delivery, expansion of biologic drug pipelines, growing investments in smart injection technologies, increasing adoption of home healthcare solutions. Major trends in the forecast period include increasing adoption of prefilled and safety syringes, rising demand for autoinjectors and pen injectors, growing use of home-based injectable therapies, expansion of wearable and implantable infusion pumps, enhanced focus on dose accuracy and patient safety.
The rising prevalence of chronic diseases is expected to propel the growth of the injectable drug delivery devices market. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Injectable drug delivery devices offer a reliable and convenient method for the administration of medications over extended periods. These devices can enhance patient adherence to prescribed treatment regimens, ensuring the effective management of chronic conditions and ultimately leading to better health outcomes. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, there would be over 35 million new cancer cases, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the injectable drug delivery devices market going forward.
Major companies in the injectable drug delivery devices market are focusing on developing advanced solutions, including wearable and smart injectors, to enhance patient convenience, improve adherence, and support self-administration of complex therapies. Wearable and smart injectors are innovative systems designed to deliver accurate doses of medications, including biologics and large-volume formulations, while reducing discomfort, minimizing user error, and improving the overall treatment experience. For example, in January 2025, Becton, Dickinson and Company, a US-based medical technology company, launched several next-generation devices, including the BD Accuspray Nasal Spray System, BD Hylok Glass Prefillable Syringe, BD Effivax Glass Prefillable Syringe, BD Libertas Wearable Injector, BD Evolve On-body Injector, BD Physioject Disposable Autoinjector, and BD Vystra Disposable Pen. These solutions feature user-friendly designs for self-administration, precise and consistent dosing for biologics and vaccines, compatibility with diverse drug formulations, and wearable formats for large-volume delivery, while ensuring sterility and safety through disposable components. The launch highlights the industry’s shift toward advanced, patient-centric injectable drug delivery systems aimed at improving adherence, comfort, and therapeutic outcomes.
In May 2025, Amneal Pharmaceuticals, Inc., a US-based provider of generic, specialty, and biosimilar pharmaceutical products, entered a strategic collaboration with Apiject Systems, Corp. to advance resilient, high-volume sterile manufacturing in the U.S. using innovative blow-fill-seal (BFS) injectable solutions. The partnership aims to increase production of sterile drug products by combining Amneal’s manufacturing capabilities with Apiject’s advanced BFS technology, strengthening the supply chain, expanding output, and enhancing the ability to produce injectables, ophthalmic treatments, and inhalation therapies. Apiject Systems, Corp. is a US-based medical technology company specializing in advanced drug delivery systems, including BFS-based injectable platforms.
Major companies operating in the injectable drug delivery devices market are Becton Dickinson and Company, Baxter International, Gerresheimer AG, Catalent Inc., Antares Pharma, Owen Mumford, West Pharmaceutical Services Inc., B. Braun Melsungen AG, Ypsomed AG, AptarGroup Inc., Nemera, Teleflex Medical, Medtronic, Caplin Steriles Limited, Hovione Technology, Jiangsu Delfu Medical Device Co. Ltd., Terumo Corporation, Roche, Sorrel Medical, Novo Nordisk.
North America was the largest region in the injectable drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the injectable drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the injectable drug delivery devices market by increasing costs of imported medical-grade plastics, stainless steel components, micro-needles, electronic sensors, and precision manufacturing equipment. Hospitals, pharmaceutical companies, and device manufacturers in North America and Europe are most affected due to reliance on global component sourcing, while Asia-Pacific faces cost pressure on export-oriented production. These tariffs are raising device manufacturing costs and affecting pricing strategies. However, they are also encouraging localized production, regional supplier diversification, and investments in domestic medical device manufacturing infrastructure.
The injectable drug delivery devices market research report is one of a series of new reports that provides injectable drug delivery devices market statistics, including injectable drug delivery devices industry global market size, regional shares, competitors with a injectable drug delivery devices market share, detailed injectable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the injectable drug delivery devices industry. This injectable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Injectable Drug Delivery Devices are medical devices specifically designed to deliver medications directly into the body via injections. These devices are utilized for multiple routes of drug administration, including intravenous, subcutaneous, intradermal, intraperitoneal, and intramuscular.
The primary types of injectable drug delivery devices include conventional injectables, pre-filled syringes, auto-injectors, and pen injectors. Pre-filled syringes come with a fixed needle and contain single-dose vaccines or other medications. These devices find applications in various medical areas such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. Injectable drug delivery devices are utilized by a range of end-users, including hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others.
The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The injectable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $79.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing shift toward self-administration devices, rising demand for personalized drug delivery, expansion of biologic drug pipelines, growing investments in smart injection technologies, increasing adoption of home healthcare solutions. Major trends in the forecast period include increasing adoption of prefilled and safety syringes, rising demand for autoinjectors and pen injectors, growing use of home-based injectable therapies, expansion of wearable and implantable infusion pumps, enhanced focus on dose accuracy and patient safety.
The rising prevalence of chronic diseases is expected to propel the growth of the injectable drug delivery devices market. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Injectable drug delivery devices offer a reliable and convenient method for the administration of medications over extended periods. These devices can enhance patient adherence to prescribed treatment regimens, ensuring the effective management of chronic conditions and ultimately leading to better health outcomes. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, there would be over 35 million new cancer cases, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the injectable drug delivery devices market going forward.
Major companies in the injectable drug delivery devices market are focusing on developing advanced solutions, including wearable and smart injectors, to enhance patient convenience, improve adherence, and support self-administration of complex therapies. Wearable and smart injectors are innovative systems designed to deliver accurate doses of medications, including biologics and large-volume formulations, while reducing discomfort, minimizing user error, and improving the overall treatment experience. For example, in January 2025, Becton, Dickinson and Company, a US-based medical technology company, launched several next-generation devices, including the BD Accuspray Nasal Spray System, BD Hylok Glass Prefillable Syringe, BD Effivax Glass Prefillable Syringe, BD Libertas Wearable Injector, BD Evolve On-body Injector, BD Physioject Disposable Autoinjector, and BD Vystra Disposable Pen. These solutions feature user-friendly designs for self-administration, precise and consistent dosing for biologics and vaccines, compatibility with diverse drug formulations, and wearable formats for large-volume delivery, while ensuring sterility and safety through disposable components. The launch highlights the industry’s shift toward advanced, patient-centric injectable drug delivery systems aimed at improving adherence, comfort, and therapeutic outcomes.
In May 2025, Amneal Pharmaceuticals, Inc., a US-based provider of generic, specialty, and biosimilar pharmaceutical products, entered a strategic collaboration with Apiject Systems, Corp. to advance resilient, high-volume sterile manufacturing in the U.S. using innovative blow-fill-seal (BFS) injectable solutions. The partnership aims to increase production of sterile drug products by combining Amneal’s manufacturing capabilities with Apiject’s advanced BFS technology, strengthening the supply chain, expanding output, and enhancing the ability to produce injectables, ophthalmic treatments, and inhalation therapies. Apiject Systems, Corp. is a US-based medical technology company specializing in advanced drug delivery systems, including BFS-based injectable platforms.
Major companies operating in the injectable drug delivery devices market are Becton Dickinson and Company, Baxter International, Gerresheimer AG, Catalent Inc., Antares Pharma, Owen Mumford, West Pharmaceutical Services Inc., B. Braun Melsungen AG, Ypsomed AG, AptarGroup Inc., Nemera, Teleflex Medical, Medtronic, Caplin Steriles Limited, Hovione Technology, Jiangsu Delfu Medical Device Co. Ltd., Terumo Corporation, Roche, Sorrel Medical, Novo Nordisk.
North America was the largest region in the injectable drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the injectable drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the injectable drug delivery devices market by increasing costs of imported medical-grade plastics, stainless steel components, micro-needles, electronic sensors, and precision manufacturing equipment. Hospitals, pharmaceutical companies, and device manufacturers in North America and Europe are most affected due to reliance on global component sourcing, while Asia-Pacific faces cost pressure on export-oriented production. These tariffs are raising device manufacturing costs and affecting pricing strategies. However, they are also encouraging localized production, regional supplier diversification, and investments in domestic medical device manufacturing infrastructure.
The injectable drug delivery devices market research report is one of a series of new reports that provides injectable drug delivery devices market statistics, including injectable drug delivery devices industry global market size, regional shares, competitors with a injectable drug delivery devices market share, detailed injectable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the injectable drug delivery devices industry. This injectable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Injectable Drug Delivery Devices are medical devices specifically designed to deliver medications directly into the body via injections. These devices are utilized for multiple routes of drug administration, including intravenous, subcutaneous, intradermal, intraperitoneal, and intramuscular.
The primary types of injectable drug delivery devices include conventional injectables, pre-filled syringes, auto-injectors, and pen injectors. Pre-filled syringes come with a fixed needle and contain single-dose vaccines or other medications. These devices find applications in various medical areas such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. Injectable drug delivery devices are utilized by a range of end-users, including hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others.
The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Injectable Drug Delivery Devices Market Characteristics
3. Injectable Drug Delivery Devices Market Supply Chain Analysis
4. Global Injectable Drug Delivery Devices Market Trends and Strategies
5. Injectable Drug Delivery Devices Market Analysis of End Use Industries
7. Global Injectable Drug Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Injectable Drug Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Injectable Drug Delivery Devices Market Segmentation
10. Injectable Drug Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Injectable Drug Delivery Devices Market
12. China Injectable Drug Delivery Devices Market
13. India Injectable Drug Delivery Devices Market
14. Japan Injectable Drug Delivery Devices Market
15. Australia Injectable Drug Delivery Devices Market
16. Indonesia Injectable Drug Delivery Devices Market
17. South Korea Injectable Drug Delivery Devices Market
18. Taiwan Injectable Drug Delivery Devices Market
19. South East Asia Injectable Drug Delivery Devices Market
20. Western Europe Injectable Drug Delivery Devices Market
21. UK Injectable Drug Delivery Devices Market
22. Germany Injectable Drug Delivery Devices Market
23. France Injectable Drug Delivery Devices Market
24. Italy Injectable Drug Delivery Devices Market
25. Spain Injectable Drug Delivery Devices Market
26. Eastern Europe Injectable Drug Delivery Devices Market
27. Russia Injectable Drug Delivery Devices Market
28. North America Injectable Drug Delivery Devices Market
29. USA Injectable Drug Delivery Devices Market
30. Canada Injectable Drug Delivery Devices Market
31. South America Injectable Drug Delivery Devices Market
32. Brazil Injectable Drug Delivery Devices Market
33. Middle East Injectable Drug Delivery Devices Market
34. Africa Injectable Drug Delivery Devices Market
36. Injectable Drug Delivery Devices Market Competitive Landscape and Company Profiles
37. Injectable Drug Delivery Devices Market Other Major and Innovative Companies
40. Injectable Drug Delivery Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Injectable Drug Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses injectable drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for injectable drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The injectable drug delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Syringes; Injectors; Pump2) By Application: Autoimmune Diseases; Hormonal Disorders; Oncology; Orphan Diseases; Pain Management; Respiratory Therapy; Other Applications
3) By End-user: Hospitals And Clinics; Home Healthcare Settings; Pharmaceutical And Biotechnological Companies; Research Laboratories; Other End Users
Subsegments:
1) By Syringes: Conventional Syringes; Prefilled Syringes; Safety Syringes2) By Injectors: Autoinjectors; Pen Injectors; Needle-Free Injectors
3) By Pumps: Insulin Pumps; Ambulatory Infusion Pumps; Implantable Pumps
Companies Mentioned: Becton Dickinson and Company; Baxter International; Gerresheimer AG; Catalent Inc.; Antares Pharma; Owen Mumford; West Pharmaceutical Services Inc.; B. Braun Melsungen AG; Ypsomed AG; AptarGroup Inc.; Nemera; Teleflex Medical; Medtronic; Caplin Steriles Limited; Hovione Technology; Jiangsu Delfu Medical Device Co. Ltd.; Terumo Corporation; Roche; Sorrel Medical; Novo Nordisk
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Injectable Drug Delivery Devices market report include:- Becton Dickinson and Company
- Baxter International
- Gerresheimer AG
- Catalent Inc.
- Antares Pharma
- Owen Mumford
- West Pharmaceutical Services Inc.
- B. Braun Melsungen AG
- Ypsomed AG
- AptarGroup Inc.
- Nemera
- Teleflex Medical
- Medtronic
- Caplin Steriles Limited
- Hovione Technology
- Jiangsu Delfu Medical Device Co. Ltd.
- Terumo Corporation
- Roche
- Sorrel Medical
- Novo Nordisk
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 58.69 Billion |
| Forecasted Market Value ( USD | $ 79.51 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
